报告给美国中毒中心的 gabapentin 和 pregabalin 暴露, 2012-2022 年
Emily J R Carter1,2, Natalie I Rine3, Sandhya Kistamgari1
1Center for Injury Research and Policy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.
Injury epidemiology
|November 2, 2024
概括
据报道,到2019年,美国中毒中心报告的 gabapentin 和 pregabalin 暴露率升超过230%,主要是 gabapentin 和与自杀有关的病例. 虽然大多数病例是轻微的,但有22%的病例是严重的,其中96人死亡.
科学领域:
- 药物监督 药物监督 药物监督
- 临床毒理学 临床毒理学
- 公共卫生 公共卫生
背景情况:
- 起初是抗药的 gabapentin 和 pregabalin 现在被广泛用于治疗各种疾病,特别是治疗疼痛.
- 包括 gabapentinoids 在内的非阿片类止痛药的使用增加与全国阿片类药物危机相吻合,可能会改变不良事件概况.
- 本研究研究了2012年至2022年间美国中毒控制中心报告的 gabapentinoid 暴露趋势.
研究的目的:
- 调查美国中毒中心报告的 gabapentin 和 pregabalin 暴露的特征和时间趋势.
- 分析与这些暴露相关的结果,包括严重程度和死亡率.
主要方法:
- 从国家毒素数据系统 (NPDS) 对2012年至2022年 gabapentin 和 pregabalin 暴露的数据分析.
- 根据物质,人口统计,暴露环境和临床结果对暴露的分类.
主要成果:
- 报告总共报告了124,161次 gabapentin 和pregabalin 的暴露.
- 从2012年到2019年,暴露率增加了236.1%,然后停滞不前,主要是由 gabapentin 和疑似自杀病例推动的.
- 虽然大多数暴露有轻微或没有影响,但22.1%导致严重的医疗结果,包括96人死亡.
结论:
- 从2012年到2019年, gabapentin和pregabalin的暴露率显著增加,随后出现了平原.
- 暴露率的增加与 gabapentin 使用和与自杀有关的事件有关,突出了公共卫生问题.
- 这些发现支持关于重新安排 gabapentin 的讨论,并强调需要与这些药物相关的自杀预防策略.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
Pharmacovigilance
776
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
776
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
255
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
255
Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
87
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
87


